273 related articles for article (PubMed ID: 15207426)
21. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
22. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
23. [Effect of apomorphine on the bladder of parkinsonian patients].
Aranda B; Cramer P; Adba MA
J Urol (Paris); 1992; 98(1):25-9. PubMed ID: 1527394
[TBL] [Abstract][Full Text] [Related]
24. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
25. Continuous dopaminergic stimulation--from theory to clinical practice.
Antonini A
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S24-8. PubMed ID: 17702632
[TBL] [Abstract][Full Text] [Related]
26. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
27. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
[TBL] [Abstract][Full Text] [Related]
28. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
Hellmann MA; Sabach T; Melamed E; Djaldetti R
Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
[TBL] [Abstract][Full Text] [Related]
29. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
30. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
31. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
32. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
33. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
34. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
Merello M; Leiguarda R
Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
[TBL] [Abstract][Full Text] [Related]
36. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
37. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH;
Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329
[TBL] [Abstract][Full Text] [Related]
38. Dopamine agonists in the treatment of Parkinson's disease.
Bonuccelli U; Pavese N
Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
[TBL] [Abstract][Full Text] [Related]
39. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
Grandas F
Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]